Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A Multicenter, observational cross-sectional study for rheumatoid arthritis

Basit Öğe Kaydı
dc.authorid0000-0002-4124-1586en_US
dc.contributor.authorAtaman, Şebnem
dc.contributor.authorSunar, İsmihan
dc.contributor.authorBodur, Hatice
dc.contributor.authorMelikoğlu, Meltem Alkan
dc.contributor.authorÇay, Hasan Fatih
dc.contributor.authorÇapkın, Erhan
dc.contributor.authorÇevik, Remzi
dc.date.accessioned2023-01-03T11:10:33Z
dc.date.available2023-01-03T11:10:33Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalıen_US
dc.description.abstractIntroduction Rheumatoid arthritis is a chronic inflammatory disease with different disease activity grades. Several registries have been designed to determine the appropriate regimens of disease-modifying antirheumatic drugs to obtain sustained clinical remission. We examined epidemiological and clinical characteristics of rheumatoid arthritis patients using a clinical registry database (BioSTaR) and analyzed the differences in patients with sustained and switched therapies. Methods A multicenter, observational cross-sectional study for rheumatoid arthritis was performed between February 2019 and September 2020 using the BioStaR-RA registry. Demographic and clinical characteristics were prospectively recorded into a specifically designed electronic database. The patients were divided into three groups due to the heterogeneity of the study cohort. Patients were grouped as Group I (Initial; within the first 6 months of treatment with biological/targeted synthetic drugs), Group ST (Sustained Treatment; any first drug lasting for at least 6 months without any change), and Group S (Switch; any switching to another drug). Comparative analysis was performed between sustained treatment (Group ST) and drug switching (Group S) groups. Results The study included a total of 565 patients. The mean age was 53.7 +/- 12.8 years, and the majority were female (80.4%). There were 104, 267, and 194 patients in Groups I, ST, and S, respectively. Erosive arthritis and hematological extra-articular involvement were more frequently detected in Group S than Group ST (p = 0.009 and p = 0.001). The patients in Group S had significantly higher disease activity scores (DAS28-CRP, CDAI, and SDAI) (p = 0.025, p = 0.010, and p = 0.003). There were significantly more patients with moderate disease activity in Group S (p < 0.05). Conclusions The groups with sustained treatment and switching included patients with different disease activity status, although higher disease activity was determined in switchers. Overall, moderate disease activity and remission were the most common disease activity levels. Lower disease activity scores, lower hematologic manifestations, better functional status, and lesser radiographic damage are associated with sustained treatment.en_US
dc.identifier.citationAtaman, Ş., Sunar, İ., Bodur, H., Melikoğlu, M.A., Çay, H.F., Çapkın, E. ve diğerleri. (2022). Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A Multicenter, observational cross-sectional study for rheumatoid arthritis. Rheumatology and Theraphy, 9(1), 223-241.en_US
dc.identifier.doi10.1007/s40744-021-00403-y
dc.identifier.endpage241en_US
dc.identifier.issn2198-6576
dc.identifier.issn2198-6584
dc.identifier.issue1en_US
dc.identifier.pmid34850376
dc.identifier.scopus2-s2.0-85120360954
dc.identifier.scopusqualityQ2
dc.identifier.startpage223en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s40744-021-00403-y
dc.identifier.urihttps://hdl.handle.net/11468/11177
dc.identifier.volume9en_US
dc.identifier.wosWOS:000723963100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇevik, Remzi
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofRheumatology and Theraphy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectDisease-modifying antirheumatic drugsen_US
dc.subjectRegistriesen_US
dc.subjectTreatment switchingen_US
dc.titleDemographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A Multicenter, observational cross-sectional study for rheumatoid arthritisen_US
dc.titleDemographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A Multicenter, observational cross-sectional study for rheumatoid arthritis
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs.pdf
Boyut:
542.76 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu